CCR5/CD195 recombinant proteins and antibodies

C-C chemokine receptor type 5 (CCR5), also known as CHEMR13, CMKBR5, CD195, is a seven-transmembrane G protein-coupled receptor (GPCR) predominantly expressed on immune cells such as T cells, macrophages, and dendritic cells. It plays a pivotal role in immune regulation, inflammation, and viral infection. CCR5 is best known as a coreceptor that facilitates HIV entry into host cells; thus, blocking CCR5 can effectively prevent HIV infection. Beyond viral diseases, CCR5 has emerged as a promising target for cancer metastasis, autoimmune disorders, inflammatory diseases, and neuroregeneration.

In drug development, CCR5 antagonists are the major focus. The first approved drug, Maraviroc (Selzentry) by Pfizer, is used for HIV treatment. In recent years, companies have been expanding the therapeutic potential of CCR5. Leronlimab (PRO 140), a monoclonal antibody developed by CytoDyn, has been investigated for HIV, metastatic breast cancer, and COVID-19. Chinese biotech companies such as Junshi Biosciences and BeiGene are also exploring CCR5-mediated immune mechanisms, particularly its role in tumor microenvironment modulation and immunotherapy enhancement.
Currently, the CCR5 drug development landscape is shifting from antiviral therapy toward oncology and immune regulation. With deepening insights into CCR5 signaling pathways, this target holds great promise as a new avenue for the treatment of multiple major diseases.

To assist in the development of CCR5 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CCR5 targets. Products include ECD recombinant proteins, the full-length membrane protein, reference antibodies, and flow-cytometry-verified anti-CCR5 monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CCR5 biotherapy, DIMA BIOTECH has also prepared a CCR5 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CCR5 lead molecules, and customers can get the molecules for functional evaluation and verification the next day.